Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2005-09-06
2005-09-06
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S300000, C514S002600, C514S014800
Reexamination Certificate
active
06939948
ABSTRACT:
The present invention provides peptide mimics for GD2 ganglioside. The peptide mimics were identified by panning phage display peptide libraries with an anti-GD2 monoclonal antibody. The identified peptide mimics can be used as immunogens for cancer therapy such as for melanoma and neuroblastoma.
REFERENCES:
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 5882654 (1999-03-01), Morton
Chapman et al.,Vaccination with a Bivalent GM2 and GD2 Ganglioside Conjugate Vaccine: A Trial Comparing Doses of GD2-Keyhole Limpet Hemocyanin, Clinical Cancer Research (Dec. 2000) vol. 6, pp. 4658-4662.
Cheung et al.,Induction of Ab3 and Ab3' Antibody was Associated with Long-Term Survival after Anti-GD2 Antibody Therapy of Stage 4 Neuroblastoma, Clinical Cancer Research (Jul. 2000) vol. 6, pp. 2653-2660.
Kramer et al.,Disialoganglioside GD2 Loss Following Monoclonal Antibody Therapy is Rare in Neuroblastoma, Medical and Pediatric Oncology (2001) vol. 36, pp. 194-196.
Kushner et al.,Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma, Journal of Clinical Oncology (Nov. 15, 2001) vol. 19, No. 22, pp. 4189-4194.
Murray et al.,Phase I Trial of Murine Monoclonal Antibody 14G2a Administered by Prolonged Intravenous Infusion in Patients with Neuroectodermal Tumors, Journal of Clinical Oncology (Jan. 1994) vol. 12, No. 1, pp. 184-193.
Qiu et al.,Towards the Development of Peptide Mimotopes of Carbohydrate Antigens as Cancer Vaccines, Hybridoma (Nov. 1, 1999) vol. 18, pp. 103-112.
Saleh et al.,Phase 1 Trial of the Murine Monoclonal Anti-GD2 Antibody 14G2a in Metastatic Melanoma, Cancer Research (Aug. 15, 1992) vol. 52, pp. 4342-4347.
Slart et al.,An Animal Model of Pain Produced by Systemic Administration of an Immunotherapeutic Anti-Ganglioside Antibody, Pain (1997) vol. 69, pp. 119-125.
Sorkin et al.,Antibody Directed Against GD2 Produces Mechanical Allodynia, but Not Thermal Hyperalgesia when Administered Systemically or Intrathecally Despite its Dependence on Capsaicin Sensitive Afferents, Brain Research (2002) vol. 930, pp. 67-74.
Tai et al.,Immunogenicity of Melanoma-Associated Gangliosides in Cancer Patients, Int. J. Cancer (1985) vol. 35, pp. 607-612.
Yu et al.,Phase 1 Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma, Journal of Clinical Oncology (Jun. 1998) vol. 16. No. 6, pp. 2169-2180.
Cheung Nai-Kong V.
Ferrone Soldano
Luo Wei
Tsao Chun-Yen
Wang Xinhui
Blanchard David J.
Health Research , Inc.
Helms Larry R.
Hodgson & Russ LLP
Sloan Kettering Institute for Cancer Research
LandOfFree
GD2 peptide mimics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GD2 peptide mimics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GD2 peptide mimics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3444919